Phase I study of combination chemotherapy with nab-paclitaxel and Nedaplatin as first-line treatment in patients with advanced squamous cell lung cancer.
Phase 1
- Conditions
- Squamous cell lung cancer
- Registration Number
- JPRN-UMIN000010963
- Lead Sponsor
- Kitasato University School of Medicine Department of Respiratory Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 16
Inclusion Criteria
Not provided
Exclusion Criteria
1) Severe infection. 2) Severe complications. 3) Uncontrollable pleural or pericardial effusion or ascites. 4) Superior vena cava syndrome. 5) Simultaneous or metachronous double cancers. 6) Symptomatic brain metastases. 7) Prior radiotherapy for primary tumor. 8) Radiotherapy other than primary tumor within 2 weeks. 9) A history of serious drug allergy or severe allergic reaction with albumin. 10) Psycologic illness
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Finding a decomending dose
- Secondary Outcome Measures
Name Time Method evaluation of safety and response rate